Pliant Therapeutics Stock Analysis
| PLRX Stock | USD 13.46 0.48 3.70% |
Pliant Therapeutics is undervalued with Real Value of 21.16 and Target Price of 46.57. The main objective of Pliant Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Pliant Therapeutics is worth, separate from its market price. There are two main types of Pliant Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Pliant Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Pliant Therapeutics is usually not traded on Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday. Pliant Stock trading window is adjusted to America/New York timezone.
Pliant |
Pliant Stock Analysis Notes
About 97.0% of the company shares are owned by institutional investors. The book value of Pliant Therapeutics was at this time reported as 5.68. The company recorded a loss per share of 3.35. Pliant Therapeutics had not issued any dividends in recent years. Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California. Pliant Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 110 people. To find out more about Pliant Therapeutics contact MBA MD at 650 481 6770 or learn more at https://pliantrx.com.Pliant Therapeutics Investment Alerts
| Pliant Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 1.58 M. Net Loss for the year was (161.34 M) with profit before overhead, payroll, taxes, and interest of 9.69 M. | |
| Pliant Therapeutics currently holds about 163.6 M in cash with (116.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.36. | |
| Pliant Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Pliant Therapeutics to Participate in Upcoming Investor Events - Yahoo Finance |
Pliant Therapeutics Upcoming and Recent Events
Earnings reports are used by Pliant Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Pliant Largest EPS Surprises
Earnings surprises can significantly impact Pliant Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-02-28 | 2021-12-31 | -0.76 | -0.68 | 0.08 | 10 | ||
2022-11-08 | 2022-09-30 | -0.74 | -0.65 | 0.09 | 12 | ||
2024-02-27 | 2023-12-31 | -0.81 | -0.69 | 0.12 | 14 |
Pliant Therapeutics Environmental, Social, and Governance (ESG) Scores
Pliant Therapeutics' ESG score is a quantitative measure that evaluates Pliant Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Pliant Therapeutics' operations that may have significant financial implications and affect Pliant Therapeutics' stock price as well as guide investors towards more socially responsible investments.
Pliant Stock Institutional Investors
| Shares | Polar Capital Holdings Plc | 2024-06-30 | 2 M | Deutsche Bank Ag | 2024-06-30 | 1.5 M | State Street Corp | 2024-06-30 | 1.4 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.3 M | Geode Capital Management, Llc | 2024-09-30 | 1.3 M | Ra Capital Management, Llc | 2024-09-30 | 1.3 M | Pictet Asset Manangement Sa | 2024-06-30 | 1.2 M | Franklin Resources Inc | 2024-09-30 | 1 M | Candriam Luxembourg S.c.a. | 2024-06-30 | 833.2 K | Deep Track Capital, Lp | 2024-09-30 | 6 M | Blackrock Inc | 2024-06-30 | 5 M |
Pliant Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 789.88 M.Pliant Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.32) | (0.33) | |
| Return On Capital Employed | (0.38) | (0.40) | |
| Return On Assets | (0.32) | (0.33) | |
| Return On Equity | (0.34) | (0.32) |
Management Efficiency
Pliant Therapeutics has return on total asset (ROA) of (0.2815) % which means that it has lost $0.2815 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4752) %, meaning that it created substantial loss on money invested by shareholders. Pliant Therapeutics' management efficiency ratios could be used to measure how well Pliant Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.33 in 2024. Return On Capital Employed is likely to drop to -0.4 in 2024. At this time, Pliant Therapeutics' Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 378.4 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 957.1 K in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 8.07 | 8.47 | |
| Tangible Book Value Per Share | 8.07 | 8.47 | |
| Enterprise Value Over EBITDA | (6.39) | (6.71) | |
| Price Book Value Ratio | 2.25 | 2.36 | |
| Enterprise Value Multiple | (6.39) | (6.71) | |
| Price Fair Value | 2.25 | 2.36 | |
| Enterprise Value | 1 B | 1.1 B |
The strategic initiatives led by Pliant Therapeutics' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Beta 1.087 | Return On Assets (0.28) | Return On Equity (0.48) |
Technical Drivers
As of the 25th of November, Pliant Therapeutics holds the Coefficient Of Variation of 8675.22, risk adjusted performance of 0.0168, and Semi Deviation of 3.19. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Pliant Therapeutics, as well as the relationship between them.Pliant Therapeutics Price Movement Analysis
The output start index for this execution was eleven with a total number of output elements of fifty. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Pliant Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Pliant Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Pliant Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pliant Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pliant Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Pliant Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Pliant Therapeutics Outstanding Bonds
Pliant Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Pliant Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Pliant bonds can be classified according to their maturity, which is the date when Pliant Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Pliant Therapeutics Predictive Daily Indicators
Pliant Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Pliant Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Pliant Therapeutics Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 7th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 4th of October 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 27th of September 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 7th of August 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 15th of July 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 12th of July 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Pliant Therapeutics Forecast Models
Pliant Therapeutics' time-series forecasting models are one of many Pliant Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Pliant Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Pliant Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Pliant Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Pliant shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Pliant Therapeutics. By using and applying Pliant Stock analysis, traders can create a robust methodology for identifying Pliant entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (102.11) | (97.01) | |
| Operating Profit Margin | (116.55) | (110.72) | |
| Net Loss | (102.11) | (97.01) | |
| Gross Profit Margin | 0.56 | 0.48 |
Current Pliant Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Pliant analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Pliant analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 46.57 | Strong Buy | 13 | Odds |
Most Pliant analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Pliant stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Pliant Therapeutics, talking to its executives and customers, or listening to Pliant conference calls.
Pliant Stock Analysis Indicators
Pliant Therapeutics stock analysis indicators help investors evaluate how Pliant Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Pliant Therapeutics shares will generate the highest return on investment. By understating and applying Pliant Therapeutics stock analysis, traders can identify Pliant Therapeutics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 33.7 M | |
| Long Term Debt | 10.1 M | |
| Common Stock Shares Outstanding | 58.7 M | |
| Total Stockholder Equity | 473.6 M | |
| Property Plant And Equipment Net | 4.8 M | |
| Cash And Short Term Investments | 494.2 M | |
| Cash | 63.2 M | |
| Accounts Payable | 4.5 M | |
| Net Debt | -51.9 M | |
| 50 Day M A | 13.1112 | |
| Total Current Liabilities | 28.5 M | |
| Other Operating Expenses | 185.7 M | |
| Non Current Assets Total | 6.7 M | |
| Non Currrent Assets Other | 1.9 M | |
| Stock Based Compensation | 44.5 M |
Additional Tools for Pliant Stock Analysis
When running Pliant Therapeutics' price analysis, check to measure Pliant Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pliant Therapeutics is operating at the current time. Most of Pliant Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pliant Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pliant Therapeutics' price. Additionally, you may evaluate how the addition of Pliant Therapeutics to your portfolios can decrease your overall portfolio volatility.